퓨어테크 헬스(PRTC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $16.50 (-3.11%), 시가총액 $0.42B, 52주 최저~최고 $14.50 ~ $19.84.
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics
퓨어테크 헬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
퓨어테크 헬스의 현재 주가는 $16.50 (-3.11%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
퓨어테크 헬스의 시가총액은 약 $0.42B입니다.
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to tre